Novavax will announce its Q1 2024 earnings this Friday, 10th May. The company reported revenues of $476m, $1.15bn, $1.98bn, and $984m in the four years since 2020, with heavy net losses in each of ...
Novavax's earnings are likely due within the next couple of weeks. The vaccine developer was part of Operation Warp Speed, receiving $1.8bn of funding from the US government to develop a COVID vaccine ...
On Thursday, Novavax Inc (NASDAQ:NVAX) reported fourth-quarter 2024 sales of $88.31 million, compared to $291 million a year, beating the consensus of $84.35 million. The decrease was due to lower ...
Lots of people are hearing about Novavax, the fourth COVID vaccine option in the U.S., for the first time, but it’s been authorized for use as a primary vaccine series since early 2022. Previously, it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback